SCHEMBL73043

SCHEMBL73043

O=C(O)c1ccc(Cl)c(Cl)c1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.54
SELL P14151 1/20 0.52
SELP P16109 1/20 0.52
ALDH1A1 P00352 5/20 0.52
KDM4E B2RXH2 4/20 0.52
HSD17B10 Q99714 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
RXFP1 Q9HBX9 1/20 0.52
DPP4 P27487 1/20 0.50
TP53 P04637 1/20 0.48
CASP1 P29466 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
AKR1C2 P52895 2/20 0.47
AKR1C1 Q04828 2/20 0.47
AKR1C4 P17516 1/20 0.47
AKR1C3 P42330 1/20 0.47
MAPT P10636 3/20 0.46
HPGD P15428 2/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30084375 1.00 TSHR (0.54) TSHRSELLSELPALDH1A1KDM4E
Lithium Ion SCHEMBL31615947 0.89 TSHR (0.44) TSHRSELLSELPALDH1A1KDM4E
SCHEMBL31615929 0.89 TSHR (0.44) TSHRSELLSELPALDH1A1KDM4E
SCHEMBL18529852 0.86 SELL (0.56) TSHRSELLSELPALDH1A1KDM4E
SCHEMBL10533170 0.84 SELL (0.60) TSHRSELLSELPALDH1A1KDM4E
SCHEMBL4069345 0.82 DPP4 (0.56) TSHRSELLSELPALDH1A1KDM4E
SCHEMBL2649879 0.82 SELL (0.64) TSHRSELLSELPALDH1A1KDM4E
SCHEMBL29941520 0.82 SELL (0.64) TSHRSELLSELPALDH1A1KDM4E
SCHEMBL29886586 0.81 TSHR (0.64) TSHRALDH1A1KDM4EHSD17B10MEN1
SCHEMBL432644 0.81 TSHR (0.64) TSHRALDH1A1KDM4EHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230157284-A1 HIGH-LOAD SOLUTION CONCENTRATES OF DICAMBA BASF CORPORATION 2023-05-25 US claimed
US-20230148590-A1 Aqueous Formulations of Dicamba BASF CORPORATION 2023-05-18 US claimed
EP-4132274-A1 HIGH-LOAD SOLUTION CONCENTRATES OF DICAMBA BASF Corporation (US) 2023-02-15 EP claimed
EP-4125365-A1 AQUEOUS FORMULATIONS OF DICAMBA BASF Corporation (US) 2023-02-08 EP claimed
CN-115426880-A Aqueous formulations of dicamba 巴斯夫公司 2022-12-02 CN claimed
CN-115361868-A High-load solution concentrates of dicamba 巴斯夫公司 2022-11-18 CN claimed
WO-2021198458-A1 AQUEOUS FORMULATIONS OF DICAMBA BASF CORPORATION (US) 2021-10-07 WO claimed
CN-109761779-A A kind of preparation method of 3,6- dichlorosalicylic acid and preparing the application in dicamba 山东润博生物科技有限公司 2019-05-17 CN claimed
CN-109761802-A A kind of preparation method of dicamba 山东润博生物科技有限公司 2019-05-17 CN claimed
CN-109761794-A A kind of salicylic complete alternation method in 3,6- dichlorosalicylic acid preparation process 山东润博生物科技有限公司 2019-05-17 CN claimed
US-20120165511-A1 PROTEIN PURIFICATION USING HCIC AND ION EXCHANGE CHROMATOGRAPHY MEDAREX, INC. 2012-06-28 US claimed
WO-2012015481-A1 FUNCTIONAL BIODEGRADABLE POLYMERS UNIVERSITY OF AKRON (US) 2012-02-02 WO claimed
WO-2011031562-A1 SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME ALLTECH, INC. (US) 2011-03-17 WO claimed
US-20110054132-A1 SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME ALLTECH, INC. (US) 2011-03-03 US claimed
US-20090130739-A1 Deactivation of mineral encapsulated nanobacteria AMERICAN STERILIZER COMPANY (US) 2009-05-21 US claimed
US-20090105465-A1 Protein Purification Using HCIC and Ion Exchange Chromatography MEDAREX, INC. (US) 2009-04-23 US claimed
CN-101218247-A Protein purification using HCIC and ion exchange chromatography MEDAREX INC (US) 2008-07-09 CN claimed
EP-1869067-A1 PROTEIN PURIFICATION USING HCIC AMD ION EXCHANGE CHROMATOGRAPHY Medarex, Inc. (US) 2007-12-26 EP claimed
WO-2006110277-A1 PROTEIN PURIFICATION USING HCIC AMD ION EXCHANGE CHROMATOGRAPHY MEDAREX, INC. (US) 2006-10-19 WO claimed
WO-1998050341-A1 METHOD OF PREPARING SALICYLOYLAMINO ACIDS EMISPHERE TECHNOLOGIES, INC. (US) 1998-11-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148590-A1 Aqueous Formulations of Dicamba BOLA2; BOLA2B, CIP2A, AQP1 TSHR 4369/4885SELL 4718/4885SELP 3898/4885
US-20230157284-A1 HIGH-LOAD SOLUTION CONCENTRATES OF DICAMBA PDHB, PDHA1, LDHB TSHR 4408/4885SELL 3763/4885SELP 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.